Your session is about to expire
← Back to Search
Precursor of Dopamine
Testing on-levodopa for Parkinson's Disease
Phase 2 & 3
Waitlist Available
Research Sponsored by University of Utah
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up outcome measures will be assessed at 1 year
Awards & highlights
Study Summary
This trial will look at how levodopa affects the cardiovascular autonomic function in patients with Parkinson's disease with and without neurogenic orthostatic hypotension.
Eligible Conditions
- Parkinson's Disease
- Orthostatic Hypotension
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ outcome measures will be assessed at 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~outcome measures will be assessed at 1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in systolic blood pressure from supine to tilt at 3 minutes
Secondary outcome measures
Validated index of baroreflex cardiovagal function
Validated index of sympathoneural function
Trial Design
2Treatment groups
Experimental Treatment
Group I: Testing on-levodopaExperimental Treatment1 Intervention
Participants will undergo autonomic testing one hour after taking their regular morning dose of levodopa.
Group II: Testing off-levodopaExperimental Treatment1 Intervention
Participants will undergo autonomic testing at least twelve hours after taking their last dose of levodopa.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Autonomic testing on and off levodopa
2022
Completed Phase 3
~40
Find a Location
Who is running the clinical trial?
University of UtahLead Sponsor
1,104 Previous Clinical Trials
1,782,493 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger